Nivolumab-induced diffuse type 2 rhinosinusitis: A case report.

Background: Nivolumab, an immune checkpoint inhibitor is used to treat advanced metastatic malignancies. Data showed that nivolumab can cause exacerbated response of T-Helper 2 cells and lead to airway inflammation.

Objective: To present the upper airway findings of a 69-year-old woman after treatment with nivolumab.